AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00964431
Drug: Indomethacin Test (lower dose)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-mg single dose
Trial: NCT00964431
Drug: Indomethacin Test (upper dose)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-mg single dose
Trial: NCT01442363
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ointment
Trial: NCT00688480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule, orally for 9 months
Trial: NCT02984384
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
Trial: NCT02984384
Drug: Low Molecular Weight Heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
Trial: NCT01299831
Drug: Olbetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours.
Trial: NCT02759120
Drug: Antimicrobial therapy: Co-trimoxazole or Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
Trial: NCT00969787
Drug: DWP05195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, oral administration, single and multiple administrations
Trial: NCT00808743
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib: 400mg twice daily, orally, 6 months
Trial: NCT00808743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
Trial: NCT01434524
Drug: LIVACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIVACT contains 13.0 g of free amino acids
Trial: NCT02711423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
Trial: NCT01839552
Drug: Fentanyl Citrate Nasal Spray (FCNS)
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02493738
Drug: Lozanoc 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozanoc 50mg single dose under fed and fasted condition
Trial: NCT01718756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
Trial: NCT01718756
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery
Trial: NCT01718756
Drug: Scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia.
Trial: NCT00524160
Drug: Fentanyl transdermal patch
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01965808
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01828034
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01400867
Drug: Cephalexin or Clindamycin or Linezolid
RxNorm normalized name: clindamycin Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
Trial: NCT03060434
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
Trial: NCT00262548
Drug: Rosuvastatin; improvement of lipid profile
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00786695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical looking Placebo, same regimen, for 14 days
Trial: NCT01103934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once daily
Trial: NCT02735070
Drug: Resfenol
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Trial: NCT02735070
Drug: Coristina d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Trial: NCT00337103
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
Trial: NCT00404352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
Trial: NCT02712944
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone
Trial: NCT00984854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
Trial: NCT02667483
Drug: DS-5141b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5141b, Subcutaneous injection
Trial: NCT01520363
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
Trial: NCT00486265
Drug: AZD4877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion administered on days 1, 2 and 3
Trial: NCT00852709
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
Trial: NCT00132418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03690388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
Trial: NCT00389116
Drug: gastrograffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ingestion
Trial: NCT01094548
Drug: Single low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
Trial: NCT01094548
Drug: Multiple low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
Trial: NCT04648865
Drug: LY3537031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04648865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT03088176
Drug: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
RxNorm normalized name: TALIMOGENE LAHERPAREP 100 MIL PFU/ML 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
Trial: NCT02250196
Drug: PEG-Asc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Trial: NCT02250196
Drug: SPMC 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Trial: NCT00144365
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04619706
Drug: FSD201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04619706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matched to FSD201 for oral administration.
Trial: NCT04446065
Drug: Previfenon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
Trial: NCT04446065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
Trial: NCT03681457
Drug: LJN452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A single dose
Trial: NCT01073865
Drug: ZD9393 (Zoladex) 10.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
Trial: NCT01073865
Drug: ZD9393 (Zoladex) 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
Trial: NCT01667666
Drug: Nebulized hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
Trial: NCT00641095
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets
Trial: NCT01526889
Drug: LFG316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFG316 administered intravitreally (IVT)
Trial: NCT01526889
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy administered in accordance with its prescribing info.
Trial: NCT02078583
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02078583
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02078583
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01990677
Drug: 25mg Eplerenone
RxNorm normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
Trial: NCT01990677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
Trial: NCT00439556
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03507556
Drug: Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Trial: NCT00571259
Drug: Heparin 1000U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Trial: NCT00571259
Drug: 4% Sodium Citrate with Gentamicin 320 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Trial: NCT00092508
Drug: Asacol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for 7 weeks
Trial: NCT00060996
Drug: Remodulin® (treprostinil sodium) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03921710
Drug: CAPA-IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
Trial: NCT03921710
Drug: Standard-IVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
Trial: NCT00353743
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00353743
Drug: doxycycline plus metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
Trial: NCT00393679
Drug: artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
Trial: NCT01195805
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet twice a day for 28 days
Trial: NCT01195805
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet twice a day for 28 days
Trial: NCT02181556
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of FOLFIRI and Aflibercept every 14 days until progression of disease
Trial: NCT03010787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple dose
Trial: NCT04348513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as with T3 solution for injection.
Trial: NCT01387321
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00703547
Drug: GSK586529 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
Trial: NCT00703547
Drug: GSK586529 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
Trial: NCT00703547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets and capsules will be provided to subjects.
Trial: NCT02084771
Drug: Intravenous Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
Trial: NCT03571087
Drug: HL140 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT03571087
Drug: HL140 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT03571087
Drug: HL140 20/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT03571087
Drug: Rosuvastatin 5mg → HL140 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT03571087
Drug: Rosuvastatin 10mg → HL140 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT03571087
Drug: Rosuvastatin 20mg → HL140 20/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Trial: NCT02693574
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01653522
Drug: Triptan
RxNorm normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01653522
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02243150
Drug: G1T28-1 (CDK 4/6 Inhibitor)
RxNorm normalized name: Cyclin-dependent kinase (CDK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02243150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no